Skip to main content
Top
Published in: Diabetologia 6/2011

01-06-2011 | Article

Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus—an adaptive response to hyperglycaemia?

Authors: A. M. K. Hansen, T. B. Bödvarsdottir, D. N. E. Nordestgaard, R. S. Heller, C. F. Gotfredsen, K. Maedler, J. J. Fels, J. J. Holst, A. E. Karlsen

Published in: Diabetologia | Issue 6/2011

Login to get access

Abstract

Aims/hypothesis

The hormone glucagon-like peptide 1 (GLP-1) is released in response to a meal from the intestinal L-cells, where it is processed from proglucagon by the proconvertase (PC)1/3. In contrast, in the adult islets proglucagon is processed to glucagon by the PC2 enzyme. The aim of the study was to evaluate if, during the development of diabetes, alpha cells produce GLP-1 that, in turn, might trigger beta cell growth.

Methods

Beta cell mass, GLP-1 and insulin levels were measured in the gerbil Psammomys obesus (P. obesus), a rodent model of nutritionally induced diabetes. Furthermore, the presence of biologically active forms of GLP-1 and PC1/3 in alpha cells was demonstrated by immunofluorescence, and the release of GLP-1 from isolated P. obesus, mouse and human islets was investigated.

Results

During the development of diabetes in P. obesus, a significant increase in GLP-1 was detected in the portal vein (9.8 ± 1.5 vs 4.3 ± 0.7 pmol/l, p < 0.05), and in pancreas extracts (11.4 ± 2.2 vs 5.1 ± 1.3 pmol/g tissue, p < 0.05). Freshly isolated islets from hyperglycaemic animals released more GLP-1 following 24 h culture than islets from control animals (28.2 ± 4.4 pmol/l vs 5.8 ± 2.4, p < 0.01). GLP-1 release was increased from healthy P. obesus islets following culture in high glucose for 6 days (91 ± 9.1 pmol/l vs 28.8 ± 6.6, p < 0.01). High levels of GLP-1 were also found to be released from human islets. PC1/3 colocalised weakly with alpha cells.

Conclusions/interpretation

GLP-1 release from alpha cells is upregulated in P. obesus during the development of diabetes. A similar response is seen in islets exposed to high glucose, which supports the hypothesis that GLP-1 released from alpha cells promotes an increase in beta cell mass and function during metabolic challenge such as diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anonymous (1995) UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44:1249–1258CrossRef Anonymous (1995) UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44:1249–1258CrossRef
3.
go back to reference Farilla L, Bulotta A, Hirshberg B et al (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149–5158PubMedCrossRef Farilla L, Bulotta A, Hirshberg B et al (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149–5158PubMedCrossRef
4.
go back to reference Bregenbolt S, Moldrup A, Blume N et al (2005) The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 330:577–584CrossRef Bregenbolt S, Moldrup A, Blume N et al (2005) The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 330:577–584CrossRef
5.
go back to reference Farilla L, Hui H, Bertolotto C et al (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397–4408PubMedCrossRef Farilla L, Hui H, Bertolotto C et al (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397–4408PubMedCrossRef
6.
go back to reference Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263–1273PubMedCrossRef Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263–1273PubMedCrossRef
7.
go back to reference Perfetti R, Zhou J, Doyle ME, Egan JM (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600–4605PubMedCrossRef Perfetti R, Zhou J, Doyle ME, Egan JM (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600–4605PubMedCrossRef
8.
go back to reference Rouillé Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270:26488–26496PubMedCrossRef Rouillé Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270:26488–26496PubMedCrossRef
9.
go back to reference Rouillé Y, Kantengwa S, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 272:32810–32816PubMedCrossRef Rouillé Y, Kantengwa S, Irminger JC, Halban PA (1997) Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 272:32810–32816PubMedCrossRef
10.
go back to reference Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224PubMedCrossRef Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224PubMedCrossRef
11.
go back to reference Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957PubMedCrossRef Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957PubMedCrossRef
12.
go back to reference Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7–36) amide. Am J Physiol Gastrointest Liver Physiol 269:G852–G860 Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7–36) amide. Am J Physiol Gastrointest Liver Physiol 269:G852–G860
13.
go back to reference Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M (2005) Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta cell function. Mol Endocrinol 19:1373–1382PubMedCrossRef Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M (2005) Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta cell function. Mol Endocrinol 19:1373–1382PubMedCrossRef
14.
go back to reference Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001–8008PubMed Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001–8008PubMed
15.
go back to reference Wideman RD, Yu ILY, Webber TD et al (2006) Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci USA 103:13468–13473PubMedCrossRef Wideman RD, Yu ILY, Webber TD et al (2006) Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci USA 103:13468–13473PubMedCrossRef
16.
go back to reference Wilson ME, Kalamaras JA, German MS (2002) Expression pattern of IAPP and prohormone convertase 1/3 reveals a distinctive set of endocrine cells in the embryonic pancreas. Mech Dev 115:171–176PubMedCrossRef Wilson ME, Kalamaras JA, German MS (2002) Expression pattern of IAPP and prohormone convertase 1/3 reveals a distinctive set of endocrine cells in the embryonic pancreas. Mech Dev 115:171–176PubMedCrossRef
17.
go back to reference Kilimnik G, Kim A, Steiner DF, Hara M (2010) Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic alpha-cells in mouse models of beta-cell regeneration. Islets 2:149–155PubMedCrossRef Kilimnik G, Kim A, Steiner DF, Hara M (2010) Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic alpha-cells in mouse models of beta-cell regeneration. Islets 2:149–155PubMedCrossRef
18.
go back to reference Thyssen S, Arany E, Hill DJ (2006) Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 147:2346–2356PubMedCrossRef Thyssen S, Arany E, Hill DJ (2006) Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 147:2346–2356PubMedCrossRef
19.
go back to reference Nie Y, Nakashima M, Brubaker PL et al (2000) Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest 105:955–965PubMedCrossRef Nie Y, Nakashima M, Brubaker PL et al (2000) Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest 105:955–965PubMedCrossRef
20.
go back to reference Kalderon B, Gutman A, Levy E (1986) Characterization of stages in development of obesity-diabetes syndrome in sand rat (Psammomys obesus). Diabetes 35:717–724PubMedCrossRef Kalderon B, Gutman A, Levy E (1986) Characterization of stages in development of obesity-diabetes syndrome in sand rat (Psammomys obesus). Diabetes 35:717–724PubMedCrossRef
21.
go back to reference Shafrir E, Ziv E (1998) Cellular mechanism of nutritionally induced insulin resistance: The desert rodent Psammomys obesus and other animals in which insulin resistance leads to detrimental outcome. J Basic Clin Physiol Pharmacol 9:347–385PubMedCrossRef Shafrir E, Ziv E (1998) Cellular mechanism of nutritionally induced insulin resistance: The desert rodent Psammomys obesus and other animals in which insulin resistance leads to detrimental outcome. J Basic Clin Physiol Pharmacol 9:347–385PubMedCrossRef
22.
go back to reference Kaiser N, Yuli M, Ueckaya G et al (2005) Dynamic changes in beta-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus−impact of glycemic control. Diabetes 54:138–145PubMedCrossRef Kaiser N, Yuli M, Ueckaya G et al (2005) Dynamic changes in beta-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus−impact of glycemic control. Diabetes 54:138–145PubMedCrossRef
23.
go back to reference Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738–744PubMedCrossRef Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738–744PubMedCrossRef
24.
go back to reference Kaiser N, Nesher R, Donath MY et al (2005) Psammomys obesus, a model for environment-gene interactions in type 2 diabetes. Diabetes 54:S137–S144PubMedCrossRef Kaiser N, Nesher R, Donath MY et al (2005) Psammomys obesus, a model for environment-gene interactions in type 2 diabetes. Diabetes 54:S137–S144PubMedCrossRef
25.
go back to reference Vedtofte L, Bödarsdottir TB, Gotfredsen CF, Karlsen AE, Knudsen LB, Heller RS (2010) Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regul Pept 160:106–114PubMedCrossRef Vedtofte L, Bödarsdottir TB, Gotfredsen CF, Karlsen AE, Knudsen LB, Heller RS (2010) Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regul Pept 160:106–114PubMedCrossRef
26.
go back to reference Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539PubMedCrossRef Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539PubMedCrossRef
27.
go back to reference Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ (1994) Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985–993PubMedCrossRef Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ (1994) Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985–993PubMedCrossRef
28.
go back to reference Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-iv inhibitor, vildagliptin, does not. Diabetes 56:8–15PubMedCrossRef Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-iv inhibitor, vildagliptin, does not. Diabetes 56:8–15PubMedCrossRef
30.
go back to reference Runge S, Wulff BS, Madsen K, Brauner-Osborne H, Knudsen LB (2003) Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 138:787–794PubMedCrossRef Runge S, Wulff BS, Madsen K, Brauner-Osborne H, Knudsen LB (2003) Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 138:787–794PubMedCrossRef
31.
go back to reference Martin B, Dotson CD, Shin YK et al (2009) Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann NY Acad Sci 1170:98–101PubMedCrossRef Martin B, Dotson CD, Shin YK et al (2009) Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann NY Acad Sci 1170:98–101PubMedCrossRef
32.
go back to reference Bosco D, Armanet M, Morel P et al (2010) Unique arrangement of alpha and beta cells in human islets of Langerhans. Diabetes 59(1):202–1210 Bosco D, Armanet M, Morel P et al (2010) Unique arrangement of alpha and beta cells in human islets of Langerhans. Diabetes 59(1):202–1210
33.
go back to reference Wideman RD, Gray SL, Covey SD, Webb GC, Kieffer TJ (2008) Transplantation of PC1/3-expressing α cells improves glucose handling and cold tolerance in leptin-resistant mice. Mol Ther 17:191–198PubMedCrossRef Wideman RD, Gray SL, Covey SD, Webb GC, Kieffer TJ (2008) Transplantation of PC1/3-expressing α cells improves glucose handling and cold tolerance in leptin-resistant mice. Mol Ther 17:191–198PubMedCrossRef
34.
go back to reference McGirr R, Ejbick CE, Carter DE et al (2005) Glucose dependence of the regulated secretory pathway in alpha TC1-6 cells. Endocrinology 146:4514–4523PubMedCrossRef McGirr R, Ejbick CE, Carter DE et al (2005) Glucose dependence of the regulated secretory pathway in alpha TC1-6 cells. Endocrinology 146:4514–4523PubMedCrossRef
35.
go back to reference Jackson RS, Creemers JWM, Farooqi IS et al (2003) Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 112:1550–1560PubMed Jackson RS, Creemers JWM, Farooqi IS et al (2003) Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 112:1550–1560PubMed
36.
go back to reference Serre V, Dolci W, Schaerer E et al (1998) Exendin-(9–39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′, 5′-monophosphate levels and β cell glucose competence. Endocrinology 139:4448–4454PubMedCrossRef Serre V, Dolci W, Schaerer E et al (1998) Exendin-(9–39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′, 5′-monophosphate levels and β cell glucose competence. Endocrinology 139:4448–4454PubMedCrossRef
Metadata
Title
Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus—an adaptive response to hyperglycaemia?
Authors
A. M. K. Hansen
T. B. Bödvarsdottir
D. N. E. Nordestgaard
R. S. Heller
C. F. Gotfredsen
K. Maedler
J. J. Fels
J. J. Holst
A. E. Karlsen
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2080-1

Other articles of this Issue 6/2011

Diabetologia 6/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.